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1. Introduction  
The stromal microenvironment has become recognized as a major factor maintaining 
physiological functions of the cells and tissue integrity and it sensitively responds 
to pathological conditions including malignant transformation. The development of an altered 
stromal microenvironment in response to carcinoma is a common feature of many tumours. 
Induced stromal changes significantly contribute to malignant cell invasion and cancer 
progression. The chapter concerns about the most important stromal alterations involved in 
progression of malignant melanoma. It has been documented that one of the reasons, why 
melanoma cells escape apoptosis is a result of multicellular nature of the disease, in which 
melanoma cells are embedded in a tissue microenvironment of multiple cell types.  
2. Malignant melanoma 
Malignant melanoma is known as a highly aggressive tumour, the prognosis of which is 
difficult to predict. This tumour represents a paradox among all solid tumours because, 
despite the fact that many prognostic markers have been identified, there is very little 
understanding of their biological significance. In fact, the prognosis of malignant melanoma 
is still only based on histological criteria such as tumour size, depth of invasion, ulcerations 
and mitotic activity. However, these parameters do not allow precise prognosis. A small-
sized tumour can metastasize very early, and, on the other hand, tumours of advanced 
stages may remain localized for many years (Heenen & Laporte, 2003). Many 
epidemiological, clinical, in vitro and in vivo studies have provided insight into the biology 
of the disease. In melanoma cells, numbers of mutations and/or deregulated expression of 
B-Raf, N-Ras, CDK2A, MDM2, PTEN, p53 have been recognised, but in addition to genetic 
abnormalities, it has been shown that interactions between tumour cells and surrounding 
stromal environment are significant. Melanoma cells are embedded in a tissue 
microenvironment of multiple cell types including keratinocytes, fibroblasts, endothelial 
cells and immunoregulatory cells.  
2.1 Tumour stroma and malignant melanoma  
The interactive signalling between tumour and stroma is very heterogeneous and 
contributes to the formation of the so-called “tumour organ”. Stroma is a compilation of 
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cells including fibroblasts/myofibroblasts, epithelial, fat, immune, vascular and smooth 
muscle cells along with extracellular matrix and extracellular molecules (Fig.1). While none 
of these cells are malignant themselves, due to their interactions with each other and directly 
or indirectly with cancer cells, they acquire an abnormal phenotype and altered function to 
form a permissive and supportive environment for tumour, known as the reactive tumour 
stroma, which largely determines the phenotype of the tumour. This abnormal interplay 
consisting of cell-cell contact and active molecular crosstalk further drives the cancer stroma 
phenotype and may result in permanent alterations in cell function. The whole process is 
similar to wound healing; in fact, tumours are called never-healed wounds. The relative 
amount of stroma and its composition vary considerably from tumour to tumour and do not 
correlate with the degree of tumour malignancy.  
 
 
Fig. 1. Interactions between melanoma cells and activated stromal microenvironment are 
complicated  and complex, and include changes in cell-cell adhesions, cell- matrix and cell-
cell interactions and angiogenesis. 
2.1.1 Stromal microenvironment 
A large range of molecules including growth factors and their receptors, degradation and 
remodelling enzymes, extracellular matrix (ECM) molecules, cytokines, interleukins, 
formation of bioactive fragments are produced to disrupt normal tissue homeostasis and act 
in a paracrine manner to induce angiogenesis, the inflammatory response, changes in 
extracellular matrix composition and increased protease activity (Bhowmick et al., 2004), 
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which affect differentiation, proliferation, migration and invasion of malignant cells, and 
support tumour spread and invasion. There is also increasing evidence that tumour stroma 
can have a more direct role in tumorigenesis by acting as a mutagen. As tumours progress, 
the cells display increased genetic instability. Conditions in the tumour microenvironment 
including oxidative stress, low pH environment and nutrient deprivation contribute to 
genetic instability through the induction of enhanced mutagenesis and an impaired DNA 
damage pathway (Bindra & Glazar, 2005). Alterations of the microenvironment are not the 
same within the whole tumour mass, conditions in the central region, where hypoxia and 
necrosis occur, differ from more viable areas found toward the periphery.  
2.1.2 Carcinoma-associated fibroblasts  
One of the most important components of stromal microenvironment are stromal 
fibroblasts. The main function of normal fibroblasts is synthesis of fibrillar extracellular 
matrix including collagens I, III, V and fibronectin. They also contribute to basal membrane 
formation by secretion of collagen IV and laminin. Carcinoma-associated fibroblasts (CAFs) 
can form a foetal-like environment. Through production of a variety of growth factors 
including basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF), transforming growth factor alpha (TGF-alpha) and the 
family of vascular endothelial growth factors (VEGFs) A, B and C. Fibroblasts are capable of 
modulating complicated interactions between epithelial and mesenchymal cells. Fibroblasts 
can also act as antigen-presenting cells and so importantly regulate the immune response. 
Besides maintaining homeostasis and integrity of healthy tissues, fibroblasts fundamentally 
contribute to tissue healing by formation of granulation tissue and scarring. In cancers, 
CAFs or myofibroblasts are believed to be a major part of a tumorous stroma. Such 
fibroblasts are phenotypically and genotypically different from normal fibroblasts 
(Bhowmick et al., 2004). They become highly proliferating cells with decreased apoptotic 
potential and increased migratory capacity.  
CAFs promote tumour progression by secreting growth factors and pro-migratory ECM 
components, as well as up-regulating the expression of serine proteases and matrix 
metalloproteinases that degrade and remodel the ECM. They also contribute to tumorous 
neoangiogenesis. Moreover, CAFs can promote progression of pre-malignant lesions or 
even act as a direct mutagen stimulating the progression of a non-tumorigenic cell 
population to a tumorigenic one (Bhowmick et al., 2004). On the other hand, fibroblasts may 
also inhibit tumour growth. However, only normal fibroblasts possess these abilities. The 
mechanisms are still not clear, though the reduction of TGF or modulation of the immune 
response via interleukin-1 (IL-1), interleukin-6 (IL-6) or inhibition of T-lymphocyte 
apoptosis have been described (Silzle et al., 2004). In in vivo models of melanoma genesis, 
both the early vertical phase and the late radial phase were repressed (Proia & Kuperwasser, 
2005). Thus normalization of the stromal microenvironment should be able to slow or even 
reverse tumour progression. 
2.2 Tumour changes in malignant melanoma 
In skin, under normal condition, tissue homeostasis determines whether a cell remains 
quiescent, proliferates, differentiates, or undergoes apoptosis. Melanocytes, after cell 
division, separate and migrate along the basement membrane; finally, they extend their 
dendrites and establish multiple contacts with keratinocytes and Langerhans cells. In the 
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state of homeostasis, keratinocytes control growth and behaviour of melanocytes through 
a complicated and complex system of paracrine growth factors and cell-cell adhesion 
molecules. Once this delicate homeostatic balance is altered, melanocyte proliferation and 
migration is stimulated, which can lead to nevi or even malignant melanoma development. 
Melanoma cells escape from the control of keratinocytes through several mechanisms 
including a decrease or loss of intercellular adhesions by down-regulation of receptors and 
proteins important for their communication with keratinocytes (E-cadherin, P-cadherin), 
loss of their anchorage to the basement membrane, because of altered expression of the 
extracellular matrix-binding integrin family, and up-regulation of receptors and signalling 
molecules important for melanoma-melanoma and melanoma-fibroblast interaction such as 
N-cadherin.  
The growth of melanoma is associated with cumulating stromal alterations. The molecular 
changes associated with the transformation of melanoma cells from the radial growth phase 
(RGP) to the vertical growth phase (VGP) and the metastatic phenotype are not very well 
defined. However, some of the genes that are critical for melanoma progression have been 
demonstrated. For example, the switch from RGP to VGP and the metastatic phenotype are 
associated with loss of the AP-2 alpha transcription factor. This loss resulted in 
overexpression of MCAM/UC18, MMP, and lack of c-KIT expression (Leslie & Bar-Eli, 
2005). AP-2 alpha also regulates two G protein-coupled receptors (GPCRs), the thrombin 
receptor protease-activated receptor (PAR-1) and platelet-activating factor receptor (PAFR). 
In turn, PAR-1 regulates the expression of gap junction protein connexin 43 and the tumour 
suppressor maspin. Activation of PAR-1 also leads to overexpression and secretion of 
proangiogenic factors such as IL-8, VEGFs, PDGF, as well as certain integrins. The ligands 
for these GPCRs, thrombin and PAF, are secreted by stromal cells, emphasizing the 
importance of the melanoma microenvironment for the progression of the disease (Braeuer 
et al., 2010). Other studies have shown that AP-2 alpha regulates additional genes involved 
in melanoma growth including E-cadherin, p21/WAF-1, Her2, Bcl-2, FAS/APO-1, 
plasminogen activator inhibitor-1 (PAI-1), hepatocyte growth factor (HGF) and insulin-like 
growth factor receptor 1 (IGFR-1). The factor is a p53 binding partner, and has been shown 
to stimulate p53-dependent transcription (Melnikova & Bar-Eli, 2008). Additionally, the 
transition of melanoma cells from RGP to VGP is associated with overexpression of 
transcription factors CREB/ATF-1 (cAMP-responsive element binding protein/activating 
transcription factor-1). Two mechanisms how overexpression of CREB and ATP-1 
contributes to the aggressive phenotype have been identified. The first one is overexpression 
of the metalloproteinase MMP-2 and the adhesion molecule MCAM/UC18; in the second 
mechanism  both proteins act as survival factors for melanoma cells. 
In malignant melanoma, tumour stroma interactions involve five main mechanisms 
influencing the growth and invasion of malignant cells, activation of which determine each 
other reciprocally: (1) changes in intercellular adhesion such as the  cadherin, catenin, Snail 
and claudin families, (2) up-regulation of growth factors and their receptors, (3) activation of 
transcription factors (the family of signal transducers and activators of transcription, 
STATs), (4) stimulation of angiogenesis, and (5) immune cell response. 
2.2.1 Cell-cell adhesions 
In normal epithelial structures, cell-cell junctions play an important role in the maintenance, 
integrity and morphology of the epithelium (Alami et al., 2003). It has been reported that the 
E-cadherin/beta-catenin system of adhesion molecules plays a crucial role in these processes 
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(Weis & Nelson, 2006). E-cadherin is a cell adhesion transmembrane molecule, a member of 
a family of functionally related transmembrane glycoproteins that mediate Ca2+-dependent 
intercellular adhesion. The adhesion is mediated via interaction with adjacent cells through 
their N-terminal ectodomains and the cytoplasmic terminal tail of E-cadherin links 
specifically to beta-catenin that binds directly to the cytoskeletal actin. A deficiency in  
E-cadherin causes loss of adherent junctions (AJs), which leads to impaired intercellular 
signalling, but not to direct tumour transformation. It has been reported that dysfunction or 
disruption of cell adhesion molecules accompanies the invasiveness and metastatic 
behaviour of malignant cells. Protein beta-catenin is a molecular sensor that integrates cell-
cell junctions and cytoskeletal dynamics with signalling pathways affecting morphogenesis, 
tissue homeostasis, and intercellular communication within tissues (Perez-Moreno & Fuchs, 
2006). Generally, beta-catenin has a dual function. It plays a key role in cell-cell adhesion by 
linking cadherins to alpha-catenin and cytoskeletal actin (Weis & Nelson, 2006). In the 
absence of Wnt signal, beta-catenin is constitutively down-regulated by a multicomponent 
destruction complex containing GSK3 beta (glycogen synthase kinase 3 beta), axin and the 
tumour suppressor APC (adenomatous polyposis coli). These proteins promote the 
phosphorylation of serine and threonine residues in the NH2-terminal region of beta-
catenin. Beta-catenin is then degraded by casein kinase CK1 and protein phosphatases PP2A 
and PP2C through the ubiquitin-proteasome pathway. Wnt signalling inhibits this process, 
leading to an accumulation of beta-catenin in the nucleus, which promotes the formation of 
transcriptionally active complexes with members of the Tcf/lef family (T-cell 
factor/lymphoid enhancer factor). The Tcf/beta-catenin heterodimers act as bipartite 
transcription factors and activate expression of the specific Wnt responsive genes that 
encode proteins regulating cell cycle, e.g. c-Myc, cyclin D1 and Pitx2 (Tetsu & McCormick, 
1999). Alterations in beta-catenin-mediated regulation have been demonstrated mainly 
during cancer development, where mutations of the beta-catenin gene CTNNB1 result in 
disruption of a large number of cellular functions leading to loss of growth control and 
neoplastic change (Voeller et al., 1998; Garcia-Rostan et al., 1999). 
The classical E-, N- and P- cadherins are expressed during various stages of melanoma 
progression. In the skin environment, E-cadherin expressed by keratinocytes and 
melanocytes prevents melanocytes from division without killing the cells, and P-cadherin is 
expressed only on the surfaces of basal layer, but not by keratinocytes or melanocytes 
(Satyamoorthy & Herlyn, 2002). During embryonic development, expression of cadherin 
subtypes correlates with the migration and segregation of different cell layers and the cell 
populations. An increase of E–cadherin expression is induced on the surfaces of 
melanoblasts prior to their entry into the epidermis, thereby forming an E-cadherin-
high/P-cadherin-low population. The cadherin expression pattern then diversifies, giving 
rise to three populations: (1) an E-cadherin-/P-cadherin-negative dermal population, (2) an 
E-cadherin-high/P-cadherin-low epidermal population, and (3) an E-cadherin-/P-cadherin-
mediate to -high follicular population. In all three populations, the patterns of expression 
are region specific. During melanoma development, expression of E-cadherin is 
progressively lost and becomes heterogeneous. In nevus cells, it is predominantly 
distributed diffusely in the cytoplasm, while in melanoma cells, it is completely absent. This 
may impair loss of terminal differentiation to melanocytes by disrupting the complex 
formation between cadherin, catenin and cytoskeleton required for strong intercellular 
adhesion. Despite the loss of E-cadherin by melanoma cells, these cells express high levels of 
N-cadherin and this switching of the profile is thought to promote their interaction with 
fibroblasts and endothelial cells. This may facilitate melanoma cells to migrate into the 
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dermis and enter the vasculature (Perlis & Herlyn, 2004). In malignant melanoma, each of 
three cadherin molecules has been evaluated as a prognostic marker in multiple 
retrospective cohort studies of varying quality with different results. In multivariable 
analysis, decreased levels of P-cadherin have been shown to be associated with faster 
disease progression in thin (<2mm) lesions, but did not reach significance for all-cause 
mortality in another study (Pacifico et al., 2005). Gain of N-cadherin expression was 
significantly associated with increased all-cause mortality in one univariate long-rank 
analysis and did not retain its significance. Decreased levels of E-cadherin have been 
associated with a metastatic phenotype, where lower mean levels of the protein were shown 
in metastatic melanomas. Significant negative trends of E-cadherin were also shown with 
Breslow thickness (Kreizenbeck et al., 2008) On the other hand, improved survival was 
described in a group of patients with retained E-cadherin expression. Interesting data were 
published by Kreizenbeck et al. (2008) who evaluated simultaneous expression of cadherins. 
Worse outcomes were described in a subset of melanomas that successfully completed 
epithelial-mesenchymal transition (EMT) – down-regulation of E- and P-cadherins and 
up-regulation of N-cadherin. But unexpectedly, one group, despite having the highest levels 
of N-cadherin in the entire cohort, displayed the best survival. In this group, E-cadherin 
continued to be expressed. Thus, high levels of N-cadherin should not always be a feature of 
EMT, but high levels of the protein may recapitulate a very early but noninvasive, 
developmental phenotype.  
In malignant melanoma, both the loss of E-cadherin and mutations of beta-catenin, leading 
to a more stable non-degradable protein, have been reported. Patients with N-cadherin and 
beta-catenin co-expression yielded a 3.29-fold increased risk of death (Kreizenbeck et al., 
2008). The impact of beta-catenin expression depends on its subcellular distribution, where 
nuclear translocation of the protein represents an unfavourable prognosis, while 
cytoplasmic locations were associated with increased disease-free survival. 
The mechanism of down-regulation of E-cadherin in malignant melanoma is still unknown. 
One possibility involves promoter inactivation attributable to hypermethylation. 
Furthermore, loss of activating protein-2 transcription factor expression as a potential 
activator of E-cadherin has been suggested. Also mutations in E-cadherin gene resulting in 
a functionally inactive protein have been detected. Ultraviolet irradiation leading to 
secretion of endothelin 1 can also down-regulate E-cadherin in melanocytes and melanoma 
cells (Jamal & Schneider, 2002), as well as tumour invasion. One of the strongest E-cadherin 
repressors is the protein Snail 1. Snail is a zinc-finger transcription factor involved in the 
process that facilitates cell movement during embryonic development. Snail 1 expression 
leads to the acquisition of fibroblastic properties by epithelial cells, facilitating their 
migration. In malignant melanoma, up-regulation of Snail 1 has been observed.  Besides 
down-regulation of E-cadherin, Snail 1 is also known to promote the nuclear localization of 
beta-catenin. Furthermore, Snail suppresses the expression of claudins and occludins (De 
Craene et al., 2005). Snail has been described to affect transcriptional expression of CYLD 
(a tumour suppressor) in melanoma cells, which finally results in N-cadherin and cyclin D1 
overexpression.  The Snail family is activated by TGF-beta. Other known Snail inductors 
manifesting high metastatic potential and often exhibiting loss of functional tight junctions 
(TJs) include RAS or ILK (integrin-linked kinase) (Massoumi et al., 2009). Furthermore, 
mutation of BRAF can lead to up-regulation of Snail as well (Massoumi et al., 2009). 
Besides AJs, cell-cell adhesions are maintained through tight junctions. In contrast to the role 
of AJs, the role of TJ proteins in cancer is less well understood. TJs are the most apical cell-
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cell contacts and are important for a barrier function that regulates the passage of ions, 
water, macromolecules, and a fence function that maintains cell polarity. A number of 
integral membrane proteins associated with TJs have been identified including occludin, 
junctional adhesion molecules and the claudin family consisting of at least 24 members 
(Dhawan et al., 2005). Tumour cells, particularly in those cancers that manifest high 
metastatic potential, often exhibit loss of functional TJs. For example, levels of zonula 
occludens (ZO-1, ZO-2) and occludins are decreased during tumour formation and 
metastasis. There are differences in claudin family expression in various tumours. While 
a decrease of claudin-7 has been found, levels of claudin-1, -2 and -3 are frequently elevated. 
Claudins encode proteins with 4 transmembrane domains, and their N- and C-terminal ends 
are located in the cytoplasm. Members of the claudin family interact with each other. In 
addition, the C-terminal domain of claudins also serves as a binding site for interactions 
with other TJs that are potentially involved in signalling. Furthermore, claudins have been 
reported to recruit and promote the activation of MMP-2, suggesting potential involvement 
in invasion and metastasis. Claudin-1 was also recently identified as a probable target of 
beta-catenin/Tcf signalling. It has also been demonstrated that claudin-1 inhibition increases 
E-cadherin expression. Expression of various claudins is regulated by EGF and TGF-beta.  
As claudins regulate paracellular transport, they are usually found at the cell membrane. 
However, these proteins have been shown to alter their subcellular localization during 
malignant progression. Benign lesions and less aggressive melanomas express claudin-1 in 
the nucleus, whereas aggressive melanomas have an abundance of the protein in the 
cytoplasm. It has been reported that for the regulation and cytoplasmic localization of 
claudin expression, protein kinases such as protein kinase A (PKA) and protein kinase C 
(PKC) are important. In benign nevi and early stage melanomas, claudin is largely 
expressed in the nucleus, while highly metastatic melanoma cells tend to have increased 
claudin-1 in the cytoplasm and at the membrane  (French et al., 2009). It is curious that in 
cases where claudin-1 is low, it is predominantly nuclear, despite abundant active PKA. This 
observation implies that the levels of claudin-1 may need to reach a certain threshold prior 
to being shuttled out of the nucleus. The significance of claudin-1 in the nucleus is unclear. It 
is known that the nuclear expression of other TJs can inhibit proliferation. But different 
results were obtained by others, claiming that nuclear translocation correlates with 
oncogenic transformation and proliferation. Cytoplasmic claudin-1 location can induce 
dramatic EMT, resulting in increased cell motility and metastatic potential.  
2.2.2 Epithelial-mesenchymal transition 
All the above-mentioned proteins (cadherins, catenin, Snail and claudins) are crucially 
involved in epithelial-mesenchymal transition. EMT refers to the process, in which an 
epithelial cell disengages from its parent tissue by losing mediators of homotypic and/or 
heterotypic cell-cell interactions in exchange for morphology and adhesions marker profiles 
consistent with a mesenchymal cell and is regarded as the first necessary step for invasion 
and metastasis (Kreizenbeck et al., 2008). This pathway is especially appropriate for 
melanoma, because EMT recapitulates a pivotal phase of melanocyte development. Normal 
melanocyte precursors are derived from the neural crest. During embryogenesis, these cells 
undergo the first EMT to disengage from the neural crest and then subsequently migrate 
through the embryonic mesenchyme until they reach their terminal locations distributed 
throughout the dermal/epidermal junction where they subsequently undergo reverse EMT 
to facilitate interactions with local keratinocytes.   
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
342 
EMT plays an important role not only in skin morphology but also in wound repair, tissue 
fibrosis and cancer progression (Nakamura & Tokura, 2011). In malignant melanoma, EMT 
contributes to the promotion of metastatic phenotype in primary tumour by supporting 
specific adhesive, invasive, and migratory properties, and it is important for promoting 
transition to the VGP. EMT is the result of the expression of mesenchymal gene products 
such as fibronectin, vimentin and metalloproteinases, and the invasion and inhibition of 
E-cadherin. For EMT induction in melanomas, all genetic abnormalities including common 
mutations and/or deregulated expression of B-Raf, N-Ras and PTEN seem to synergize with 
microenvironmental factors including cell-cell interaction and angiogenic efficiency. In 
addition, it has been shown that hypoxia promotes melanocyte transdifferentiation and 
melanoma migratory and invasive abilities through up-regulating of genes normally 
associated with the extracellular matrix remodelling and invasion. These genes include 
laminin, urokinase and genes encoding matrix metalloproteinases. Furthermore, different 
microenvironments may be selective for higher levels of B-Raf-dependent and B-Raf-
independent ERK1/2 activation. These microenvironments are critical for tumour cell 
proliferation and spread. It has been shown that expression levels of phosphorylated 
ERK1/2 are not always correlated with the station status of B-Raf or N-Ras, suggesting that 
other factors promote ERK1/2 activation. Among these factors are growth factor autocrine 
loops such as the CDF-dependent activation of c-Kit, and extracellular signals. The above 
findings exemplify how the microenvironment can complement aberrant genetic changes to 
promote melanomagenesis and to support an invasive cell phenotype (Lin et al., 2010). In 
contrast to a general conception that invasion and dissemination occur during the later 
vertical phase, recent findings show that early dissemination of tumour cells that have not 
fully progressed contributes to subsequent development of metastasis. Moreover, B-RAF 
mutation is associated with constitutive hyperactivation of survival/antiapoptotic pathways 
such as the MAPK, NF-kappaB, and PI3K/AKT, which may also initiate EMT. All pathways 
cross-talk and regulate each other’s activities and functions. For instance, the NF-kappaB 
pathway directly regulates EMT through the transcription of gene products involved in 
EMT such as COX-2. Metalloproteinases and VEGFs in metastatic lesions directly and 
indirectly induce Snail through the transcriptional up-regulation. Snail in turn suppresses 
the expression of the metastasis suppressor gene product Raf kinase inhibitor protein RKIP 
(inhibits the MAPK and NF-kappaB pathways) as well as PTEN (inhibits the PI3K/AKT 
pathway). Hyperactivation of NF-kappaB greatly increases the metastatic potential, while 
knockdown of NF-kappaB reverses the mesenchymal-like phenotype and suppresses the 
motility and invasion capacity of melanoma cells (Lin et al., 2010). 
EMT accelerates cancer metastasis through not only enhanced invasion but also via 
induction of immunosuppression. Human melanocytes with typical EMT features after Snail 
transduction induce regulatory T cells and impair dendritic cells in vitro and in vivo. 
Intratumoral injection with a Snail-specific monoclonal antibody inhibits tumour growth 
and metastasis followed by an increase of tumour-specific tumour-infiltrating lymphocytes 
and systemic immune response (Kudo-Saito et al., 2009). 
Moreover, there are several new theories that EMT may also contribute to formation of 
malignant stroma when normal or cancer epithelial cells may be a source of carcinoma-
associated fibroblasts largely involved in cancer progression. 
2.2.3 Growth factors in melanoma progression 
There is a large number of growth factors and their receptors and cytokines, which by 
means of autocrine and paracrine effects are associated with melanoma progression. Those 
considered to have the highest impact are dealt with in this review. 
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Fibroblast growth factors  
Fibroblast growth factors (FGFs) are proteins with diverse functions in development, repair, 
and metabolism. The 22-member human FGF gene family includes FGF 1 – FGF 23; FGF 15 
has not been identified in humans (Itoh, 2010). FGFs can be subdivided by their action 
mechanism into three groups: (1) the intracellular FGF 11/12/13/14 subfamily, (2) the 
hormone-like (endocrine) FGF 19/21 (23) subfamily, and (3) the canonical FGF subfamily 
comprising FGF 1/2/5, FGF 3/4/6, FGF 7/10/22, FGF 8/17/18 and FGF 9/16/20 (Itoh & 
Ornitz, 2008). Canonical FGFs mediate their biological responses as extracellular proteins by 
binding to and activating cell surface tyrosine kinase FGF receptors (FGFRs) including 
FGFR-1, -2 and -3 with heparin/heparan sulfate as a cofactor. They act as local signalling 
molecules in an autocrine/paracrine manner. Two members of the FGF family, acidic FGF 
(FGF1) and predominantly basic FGF (FGF-2), are related to melanoma progression. Basic 
FGF (bFGF) protein is known as a mitogen stimulating proliferation of mesenchymal, 
epithelial and neuroectodermal cells.  The protein has been shown to stimulate proliferation 
of human melanocytes and also to support the growth and invasion of melanoma cells. The 
aberrant expression of bFGF occurs at an early stage of melanocyte lesions affecting growth 
and cell dedifferentiation. The protein is expressed not only by melanocytes or 
melanoblasts, but also by stromal cells, especially by activated fibroblasts. It is believed that 
aberrant expression of the protein even belongs to early changes stimulating proliferation 
and dedifferentiation of melanocytic lesions.  Increased bFGF expression can be induced by 
exposure to UV radiation, with abnormal expression of the protein resulting in inactivation 
of some tumour suppressors. Halaban et al. (1988) found bFGF only in malignant melanoma 
cells and characterized it as a significant autocrine factor influencing melanoma growth. 
However, these findings have not been confirmed by other studies (Ugurel  et al., 2001), 
where bFGF has also been described in cells of conventional benign nevi, although 
significantly less often. It seems to be more probable that bFGF cannot be considered 
a marker of melanocyte transformation and it can stimulate cell growth under benign as 
well malignant conditions. On the other hand, when bFGF was cleaved by thrombin, which 
imparted its biological activity, proliferation, chemotaxis and invasion of melanoma cells 
were observed (Totta et al., 2009). The function of bFGF may also be influenced by varying 
subcellular localization. Whilst in malignant melanomas, the protein is localized in the 
cytoplasm, its nuclear expression predominates in nevus cells. Cytoplasmic localization is 
associated with stimulation of VEGF and HIF expression in tumorous and stromal cells via 
activation of a variety of kinases such as PI-3K and MAPK. This location may reflect an 
aberrant form of the bFGF molecule, which is either incapable of nuclear transport or 
a possible defect in the bFGF-driven cascade may exist. It is possible that the different 
localization may be a key to another effect of bFGF, for example on the growth of malignant 
lesions and/or stimulation of fibrotization and maturation of benign nevi. In advanced stage 
III or IV melanomas, a significant increase in plasma bFGF levels has been found. These 
results even show that increased bFGF is a more sensitive parameter than detection of S-100 
protein or VEGF. The protein bFGF is suggested to be one of the candidates of early 
detection of lymph node metastases (Kurschat et al., 2007). 
Hepatocyte growth factor 
Hepatocyte growth factor/scatter factor (HGF/SF) is a potent angiogenic factor and 
mediator of epithelial cell motility, morphogenesis and angiogenesis. HGF is a mediator of 
mesenchymal-epithelial interactions that stimulates cell proliferation, migration and 
morphogenesis through its receptor c-met. HGF/SF is an essential mesenchyme-derived 
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factor in epithelial–mesenchymal (or stromal) interactions during organogenesis, 
maintaining homeostasis and regeneration of a variety of normal tissues. Moreover, 
HGF/SF is involved in tumorigenesis in vivo (Bellusci et al., 2004). The protein is considered 
to be expressed by CAFs and contributes to the microenvironment alteration (Dali et al., 
2007). Delehedde et al. (2001) showed that HGF/SF is secreted by melanoma cells. HGF 
induces fibronectin expression and its extracellular assembly on the surface of melanoma 
cells through activation of the mitogen-activated protein (MAP) kinase pathway, and 
induction and transcriptional activation of early growth response 1. Altogether this 
autocrine HGF signalling seems to have important implications in regulation of melanoma 
progression.  
Transforming growth factor beta 
TGF-beta is a paracrine growth factor, which under normal physiological conditions maintains 
tissue homeostasis via proliferation and apoptosis. It also has strong immunosuppressive 
effects. On the contrary, in cancers, this factor stimulates cell proliferation and growth and can 
protect malignant cells from the attack by the immune system.  
TGF-beta modulates the microenvironment to the benefit of tumour growth and invasion 
(Lázár-Molnár et al., 2000). TGF-beta stimulates angiogenesis, CAF proliferation, and 
extracellular matrix and cytokine production. It is also considered to be involved in EMT 
(Prud’homme, 2007). TGF-beta is generally secreted in an inactive form and requires prior 
activation. It has been documented that most mammalian cells including melanoma cells, 
express TGF-beta (Moretti et al., 1999), while melanocytes can produce latent TGF-beta only 
after stimulation by exogenous growth factors such as insulin-like growth factor 1. TGF-beta 
is a marker of advanced progression of malignant melanomas (Moretti et al., 1999). TGF-
beta has an inhibitory effect on melanocytes and early lesions, but not on advanced stage 
melanomas. In some cases, it switches to an autocrine stimulator (Lázár-Molnár et al., 2000). 
However, the role of TGF-beta as a potential autocrine growth factor is more complex. 
Experimentally, factors such as TGF-beta can induce normal fibroblasts to become activated 
and express alpha SMA (smooth muscle actin), but it is not clear if these cells acquire other 
characteristics of CAFs, and if the phenotype is stable, or if they can recover again to 
a normal state. 
Platelet-derived growth factor  
PDGF drives cellular responses including proliferation, survival, migration and deposition of 
extracellular matrix and tissue remodelling factors (Hoch & Soriano, 2003). Besides its 
mitogenic activity, this factor has its own transforming ability. The important sources of the 
protein are not only malignant cells themselves, but also activated macrophages, fibroblasts, 
smooth muscle and endothelial cells and epidermal keratinocytes. PDGF acts through the 
platelet-derived growth factor receptor (PDGFR) family of receptors tyrosine kinases. These 
receptors are expressed by a range of cell types, in which they regulate cell growth and 
proliferation by activation of signalling pathways that include BRAF-MAPK and PI-3 
pathways. PDGF is a known stimulator of tumorous stroma especially by its ability to 
modulate and activate stromal fibroblasts. Also important is its role in stimulation of 
angiogenesis. But PDGF contributes to morphological changes of new blood and lymph 
vessels, which are typical for tumorous microcirculation. It has been reported that molecules 
activated by PDGF via its receptors increase interstitial fluid pressure and in this way 
contribute to tumour chemoresistance. On the other hand, when PDGFRs and their ligands are 
blocked, there is increased therapeutic drug delivery to a tumour region (Ogawa et al., 2008).  
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Expression of PDGF in benign melanocytic lesions is low, a significant increase has been 
described in melanomas. Higher PDGF expression is documented not only in cells of 
primary skin melanomas but also in their metastases, emphasizing its importance as 
a growth factor in melanoma progression.  Thus, PDGF has become a potential aim in anti-
melanoma therapy that not only influences melanoma cells themselves but also importantly 
modulates a stromal response. 
Epidermal growth factor receptor  
EGFR belongs to the family of tyrosine kinase receptors governing cell proliferation, 
differentiation and transformation in a range of malignancies, mainly through activation of 
PI-3KAKT and MAPK pathways. EGFR also inhibits apoptosis and stimulates cell 
migration. EGFR has a direct effect on the stromal microenvironment including stimulation 
of angiogenesis and an increase of MMP-1 levels, which potentiate invasion of cancer cells. 
EGFR may also raise metastatic potential including inhibition of TGF-beta or MMP 
activation. 
The main EGFR ligands include EGF and TGF-alpha. While increased expression of EGFR 
has been well described in many cancers such as colon, stomach, lung and breast 
carcinomas, where it correlates with a worse prognosis, its role in melanoma biology is less 
clear. EGFR is one of factors whose phosphorylation and activation are influenced by UV 
radiation. But in some cases, induction of apoptosis in cells exposed to UV radiation 
accompanied by inhibition of EGFR expression has been demonstrated. Transactivation of 
EGFR may also lead to increased stability of poly(ADP-ribose) polymerase (PARP) protein 
involved in DNA repair and associated with UV stress. In vitro studies have shown increased 
cell proliferation, when EGFR was transfected to melanoma cell lines. This is in contrast to in 
vivo studies using implantation of melanoma cells, where decreased EGFR together with 
growth inhibition have been documented. It seems that EGFR levels are modulated during 
melanoma growth, with one of important modulators being the immune system (Diaz et al., 
2009).  EGFR is increased not only in melanoma lesions including both early- and late-stage 
melanomas but also in benign nevi. It seems probable that different effector pathways are 
activated. Anti-apoptotic and proliferating effects predominate in melanoma cells while in 
nevi, DNA repairs are stimulated. What conditions and mechanisms determine the function is 
not clear. FGF 1 is related to the achievement of an angiogenic phenotype of melanoma cells. 
Vascular endothelial growth factors  
VEGFs possess the leading role among the factors regulating tumour angiogenesis. VEGFs 
and their receptors have been established as distinctive proteins playing a role in endothelial 
cell proliferation and/or elongation, migration and vascular morphogenesis. VEGFs are 
produced by a variety of cell types including keratinocytes, macrophages, mast cells, 
smooth muscle cells, endothelial cells and fibroblasts. VEGF-A is the most well-
characterized member of the family of structurally related proteins that act as endothelial 
cell (EC) mitogens and angiogenic factors. VEGF-A is a dimeric glycoprotein with structural 
homology to PDGF (Ferrara et al., 1991). One of the most striking characteristics of the factor 
is its ability to induce vascular permeability. This enhanced permeability leads to 
subsequent fibrin deposition in the extracellular matrix that can then serve as a scaffold for 
migrating endothelial cells. VEGF-C, a structural homologue with VEGFs and PDGF, has 
been shown to stimulate the growth of the lymphatic endothelium and thus induce 
lymphangiogenesis.  
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The known responses of VEGFs are mediated through their receptors (VEGFRs) including 
VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3. The activation of VEGFRs by its 
ligands results in enhanced permeability of the vasculature and increased migration and 
proliferation of endothelial cells, making them also major targets for therapy (Rosen, 2002). 
VEGFs bind and activate two receptors, VEGFR-1 and VEGFR-2. The binding-affinity of 
VEGFR-1 for VEGF-A is one order of magnitude higher than that of VEGFR-2, whereas the 
kinase activity of VEGFR-1 is about 10-fold weaker than that of VEGFR-2 (Shibuya, 2006). 
VEGFR-1 plays a dual role: (1) a negative role in angiogenesis in the embryo most likely by 
tramping VEGF, and (2) a positive role in adulthood in a tyrosine kinase-dependent manner. 
VEGFR-2 has strong tyrosine kinase activity and it transduces the major signals for 
angiogenesis. VEGFR-2 is a direct signal transducer for pathological angiogenesis including 
cancer (Shibuya, 2006). VEGF-C binds and activates VEGFR-2 and VEGFR-3. VEGFR-3 is 
essential for the development of the lymphatic vasculature. Experimental tumours that 
overexpress VEGFR-3 ligands induce lymphatic vessel sprouting and enlargement and 
show enhanced metastasis to regional lymph nodes (Laakkonen et al., 2007). In melanocytic 
lesions, VEGF-A was shown to be expressed in benign as well malignant lesions, but 
malignant melanomas product the protein in significantly higher levels. However, there are 
different findings considering VEGF-A expression in moles, and some authors strictly deny 
their expression in nevus cells and they correlate increased production of the protein only 
with malignant transformation (Gorski et al., 2003; Goydos et al., 2003). Moreover, VEGF-A 
has been correlated to the transition from the radial to vertical growth phase. But it seems 
more likely that the factors can regulate angiogenesis under benign and malignant 
conditions and their detection can serve for differentiation of biological character of the 
lesion . The most important impact has deregulated and prolonged expression of VEGF-A in 
melanomas. Contrary to this, VEGF-C was shown to be mostly negative in nevi, and its 
expression seems to be directly associated with malignant transformation. Both factors are 
expressed already in early-stage melanomas, and it has been documented  that the 
expression is regulated not only by hypoxia-inducible factor (HIF) caused by hypoxic 
conditions in larger tumours but also by numbers of cytokines and growth factors (Kyzas et 
al., 2005). VEGFs are significantly increased in stromal elements surrounding melanoma 
cells, especially in advanced melanomas. Local levels of VEGFs precede their serological 
levels described in stage IV melanoma (Pelletier et al., 2005). 
VEGFRs are specific not only for endothelial cells but also for fibroblasts, tumour and immune 
cells. The role of VEGFRs is well recognised during embryonic development, but their impact 
in tumours is less clear (Shibuya, 2006). While some melanomas express increased levels of the 
receptors, others are completely negative. VEGFs are likely to be at least partly independent on 
their receptors. On the other hand, there are results exhibiting better prognosis of tumours, 
which express VEGFR-1. One explanation may be that VEGFs may bound-out free VEGFs and 
thus block their effector pathway (Yamaguchi et al., 2007). From this point of view, it may be 
possible that VEGFR-negative melanomas would have a worse prognosis. 
2.2.4 Activation of transcriptional factors 
In melanoma progression, a variety of transcriptional factors have been described. The 
leading role is believed to belong to the c-Myc oncoprotein and STAT family.  
c-Myc 
It is known that the c-Myc proto-oncogene stimulates cell proliferation and inhibits 
differentiation. The protein has also its own transforming potential. Increased expression of 
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c-Myc was described already in early stages of melanoma development, but significant 
deregulation was mostly bound to advanced stages. Autocrine production of c-Myc by 
melanoma cells stimulates their growth and dedifferentiation, but simultaneously c-Myc 
may stimulate proliferation of fibroblasts in a paracrine way and thus form tumorous 
stroma (Gu et al., 2001). Moreover, c-Myc has been found to be expressed in increased levels 
by stromal fibroblasts. Such production markedly contributes to stromal autoregulation. 
In tissues, the c-Myc oncoprotein is stabilized and its effector function is therefore 
potentiated by FGF (Lepigue et al., 2004). It has been demonstrated that oncogenic signals 
outgoing from CAFs may stimulate transformation of a non-tumorous cell population to 
a tumorous one. c-Myc is one of molecules that through the stromal compartment may 
transform cells and/or contribute to accumulation of mutations and to selection of more 
aggressive cell clones. 
Signal transducers and transcriptional activators  
STATs form a family of 7 proteins (STAT 1, 2, 3, 4, 5A, 5B and 6), which are involved in 
activation of a variety of genes. Some of them are involved in malignant transformation (Yu 
& Jove, 2004). These proteins have dual roles as cytoplasmic signalling proteins and as 
nuclear transcriptional factors that activate a diverse set of genes including some that are 
implicated in malignant progression. In normal cells, STAT proteins transmit cytoplasmic 
signals from polypeptide cytokines, specifically interferon (IFN) and IL-6, and growth 
factors that have receptors with intrinsic or associated tyrosine kinase activity, especially 
EGFR and PDGF. 
STATs are activated by phosphorylation at TYR 701, which results in their dimerization and 
translocation to the nucleus, where they directly regulate gene expression. The 
phosphorylation may also be mediated by some non-receptor kinases such as SRC and BCR-
ABL. Physiologically, ligand-dependent activation of STATs is a transient process lasting for 
several minutes to several hours. In tumours, their constitutive activation associated with 
their increased transcriptional initiation and stimulation of cell proliferation has been 
described. STATs have been shown to inhibit apoptosis by an increase of anti-apoptotic 
proteins such as BCL-XL and surviving, or a decrease by p53 protein. Moreover, STATs may 
stimulate expression of cyclins D1 and D2 and c-Myc oncoprotein.  
STATs markedly regulate tumour angiogenesis by increased expression of VEGFs and  
HIF-1. They may also modulate the immune response, when both decrease of pro-
inflammatory and stimulation of anti-inflammatory cytokines and chemokines have been 
demonstrated. STATs are also able to inhibit dendritic cell differentiation, which may result 
in an induction of cell tolerance. STATs may stimulate migration and invasion of malignant 
cells via induction of MMP-2 as well. Despite close structural homology of the STAT family, 
the responses of its individual members differ, depending on activating ligands.  
STAT 1 and STAT 2 respond to interferons, STAT 3 to IL-6, STAT 4 and STAT 6 to IL-12/16, 
whereas STAT 5 is activated mainly by growth factors and prolactin. In malignant 
melanoma, increased levels of STAT 3 have been found, in comparison with moles, where 
their concentrations are generally low (Messina et al., 2008).  STAT 3 is associated with 
an increased metastatic potential as its deregulated levels were observed in advanced and 
metastatic melanomas. In several STAT- negative cell lines, increased apoptosis or G1 arrest 
have been demonstrated. STAT 3 may affect the response to IFN-alpha adjuvant therapy in 
melanoma cells. On the one hand, a decreased antiproliferative effect of the cytokine may be 
observed. On the other hand, its activation may stimulate tumour progression. Similar 
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effects on melanoma formation and progression are seen in STAT 5, which is associated 
with Bcl-2 overexpression. STAT 1 seems to have an opposite role with its pro-apoptotic and 
anti-angiogenic effects (Ho et al., 2006). Inducibility of STAT 1 activation significantly and 
favourably influences disease-free interval and overall survival. By contrast, low expression 
of STAT 1 after administration of IFN-alpha may mean that the tumour is resistant to the 
therapy. Wang et al. (2007) suggested to evaluate the STAT 1/STAT 3 ratio, with a high ratio 
referring to a favourable clinical response. The critical antitumour action seems to be the 
activation of STAT 1 in immune effector cells. 
2.3 Angiogenesis 
Angiogenesis is an example of how tumour stroma differs from normal connective tissue. 
The induction of new blood vessel growth into tumours from pre-existing vascular beds has 
been reported as a parameter of potential prognostic value in solid tumours, as it may 
facilitate tumour growth and metastasis (Miller, 2004). By contrast, normal adult vasculature 
is generally quiescent in nature, with endothelial cells dividing approximately every 10 
years. Extensive angiogenesis occurs normally only during the female reproductive cycle 
and in body repair processes such as wound healing. 
It has been shown that for their growth beyond 1-2 mm in size, solid tumours require 
constant vascular growth and remodelling (Folkman, 1990). In tumour growth, angiogenesis 
is uncontrolled and unlimited in the time and the transition from the avascular to the 
vascular phase is called the angiogenic switch, in which the balance between angiogenesis 
inducers and inhibitors lean towards the former (Ribatti et al., 2007). Studies on human 
breast carcinomas have even shown that vascular stroma formation occurs before invasion 
by tumour cells (Gallagher  et al., 2005). Tumour vasculature differs from non-tumour not 
only by an increased number of newly formed vessels, but also by their different structure, 
organization and function, instead of regular arrangement. The vessels are distributed 
irregularly, being morphologically heterogeneous and typically thin-walled. The basal 
membranes are incomplete, partly degraded, with a reduced amount of laminin. They have 
activated endothelial cells and often lack pericytes in the periphery. The typical hallmark of 
tumour vasculature is its increased permeability. The origin of the vessels is mostly in 
activated and proliferating endothelial cells, but they may also be formed from circulation 
bone marrow progenitor cells.  
In melanoma, parallel with progression, tumours acquire a rich vascular network, whereas 
an increasing number of tumour cells express the laminin receptor, which enables their 
adhesion to the vascular wall, favouring tumour cells extravasation and metastases 
(Mahabeleshwar & Byzova, 2007). Melanoma neovascularization has been correlated with 
poor overall survival, ulceration and increased rate of relapse (Ribatti et al., 2005). 
Numerous cytokines, growth factors and extracellular matrix enzymes are associated with 
neoangiogenesis. They are produced by tumour cells themselves, but their important 
sources also include stromal elements such as fibroblasts, macrophages, mast cells and 
endothelial cells, as well as epidermal keratinocytes. The central role is played by the VEGF 
family via direct stimulation of endothelial cell migration and proliferation, permeability 
and adhesion among endothelial and tumour cells (Fig. 2).  
Very important in tumour angiogenesis is bFGF, which can stimulate vascularization by 
activation of HIF-1 and the subsequent release of VEGFs or it may also act synergistically 
with VEGFs, but with distinctive effects on vessel function and with different consequences 
on tumour oxygenation and viability. Tumours with bFGF expression are characterized by 
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a striking heterology in blood vessel diameter with numerous large-calibre vessels. FGF 
down-regulation has a profound impact on microvessel morphology, causing a significant 
decrease in diameter heterogeneity and disappearance of large-calibre vessels. FGFs do not 
possess the ability to mediate a chemotactic response for pericytes and myofibroblasts, as is 
known for VEGFs (Giavazzi et al., 2003). 
Other important stimulators of melanoma angiogenesis are PDGF and TGF-beta that 
directly stimulate VEGF-A secretion, or IGF 2, EGFR, HSP 90, STAT 3 acidosis and hypoxia 
that stimulate VEGF indirectly through activation of  HIF  gene transcription. 
An important role is also played by placental growth factor (PGF), which binds neuropilin-1 
and neuropilin-2 receptors expressed on endothelial cells. In addition, PGF acts through 
binding to VEGFR-1 inducing the mobilization and recruitment of hematopoietic precursors 
from bone marrow. Moreover, PGF forms heterodimers with VEGF-A and enhances 
melanoma angiogenesis by activating VEGFR-2 on endothelial cells (Ria et al., 2010). 
Endothelial cell migration and vascular permeability may also be induced by IL-6 derived 
from melanoma cells. It is known that levels of the cytokine dramatically increase in 
majority of melanomas and are correlated with rapid tumour growth and increased 
metastatic potential. Integrins overexpressed on melanoma cells may also contribute to 
melanoma progression and increased metastatic potential by stimulating MMP-2 and  
MMP-7 (Kuphal et al., 2005). MMP overexpression has been correlated with increased 
microvascular density, Bcl-2 overexpression and low survival rate. Several studies using 
either cell lines or animal models have demonstrated that the balance between MMPs and 
their inhibitors (TIMPs) finally determines melanoma progression. Overexpression of TIMPs 
reduces melanoma cell invasion, migration, tumour neovascularization and risk of 
metastases. MMPs and TIMPs may act as regulators of signalling pathways through the 
cleavage of non-matrix substrates including cytokines, chemokines and growth factors. 
 
 
Fig. 2. Main factors involved in melanoma angiogenesis. 
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2.4 Therapy of malignant melanoma 
Up to now, there has been no effective curative treatment of malignant melanoma beyond 
surgical excision of the primary lesion. Chemotherapy and immunotherapy have thus failed 
to make an impact on survival in the metastatic setting, while immunotherapy leads to 
modest improvement in survival in the adjuvant setting. Recent data have shed light on 
anti-melanoma targeted therapies, whereas successful management of malignant melanoma 
treatment will benefit from the identification of essential regulatory pathways and 
molecular switches underlying the plastic tumour cell phenotype and its unique interactions 
with the microenvironment.  
This review presents data on the most promising agents in development. However, it is 
important to note that all these agents have been used singly or in combination with 
chemotherapy. It has become quite apparent that the inhibition of one pathway can lead to 
up-regulation of other related or redundant pathways. This may negatively affect its activity 
or likely lead to resistance. Therefore, combination of therapies utilizing these agents seems 
to be most promising approach in the future. Targeted molecular therapeutics are tailored to 
genetic abnormalities that are associated with tumour progression. These possible targets in 
melanoma include the RAS-MAPK and PI3K/AKT signal transduction pathways, resistance 
to apoptosis, the proteasome, melanoma-induced angiogenesis, and immunotherapy 
(Tab.1). Most agents are in early phase trials, although some have already reached phase III 
evaluation. As knowledge and experience with targeted therapy advance, new challenges 
appear to be arising particularly in terms of resistance and appropriate patient selection. 
 
Inhibitors of RAS-MAPK signal transductor 
pathway 
Sorafenib 
Inhibitors of the PI3K/AKT signal 
transduction pathway 
 
Rapamycin and its analogues RAD001, 
AP23573m and CCI-779 
Imatinib mesylat 
R115777 (Lonafarnib) 
Reversing resistance to apoptosis 
 
Oblimerson sodium 
YM155 
Inhibitors of the proteasome Bortezomib 
Anti-angiogenic therapy 
 
Bevacizumab 
Thalidomide 
Anti-angiogenic  isoforms of VEGF 
Vitaxin (MEDI-552)  
Immunotherapy 
Interleukin-2 
Interluekin-2 with peptide vaccination 
Ipilimumab 
Table 1. Targeted therapy in malignant melanoma 
2.4.1 Inhibitors of the RAS-MAPK signal transduction pathway 
The importance of the RAS-MAPK signal transduction pathway for the genesis of 
melanoma has been highlighted by the discovery of activating BRAF mutations in 60% of 
cutaneous melanoma. Constitutive activation of the RAS pathway occurs through 
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mutational activation of the RAS oncogene and of downstream components. Numerous 
inhibitors have been developed including direct inhibitors of RAF such as sorafenib. 
Sorafenib 
Currently, only preliminary results of small- to medium sized phase II clinical trials are 
available for metastatic melanoma.  In addition to blocking BRAF in tumour cells, it was also 
found that sorafenib blocks other receptors effectively, including VEGFR2, PDGFR, Flt3 
(FMS-like tyrosine kinase), c-Kit and RET receptor kinases.  As a single agent, however, 
Sorafenib seems to have little or no antitumour activity in advanced melanoma patients (Ott 
et al., 2010). The most promising results so far have been observed for combination of 
multikinase inhibitor sorafenib and chemotherapy, whereas sorafenib has been found to 
enhance the response of melanoma to regional chemotherapy. The main toxicities observed 
were grade 3/4 chemotherapy-related neutropenia and thrombocytopenia. No serious 
additional toxicity of sorafenib added to carboplatin and paclitaxel was obvious (Kirkwood 
et al., 2006). Discovery of markers for predicting response to sorafenib might be useful. In 
melanomas, it has been documented that high VEGFR2 expression is associated with 
response, whereas high ERK1/2 is associated with resistance (Jilaveanu et al., 2011). 
2.4.2 Inhibitors of the PI3K/AKT signal transduction pathway 
The phosphoinositide 3-kinase (PI3K) pathway is responsible for the production of 
3-phosphoinositide lipid molecules that serve as second messengers in the cells. The 
pathway controls a cascade of signals that regulates basic cellular properties including 
survival, motility and apoptosis resistance. Multiple mechanisms for activation of the 
pathway have been identified such as amplification and overexpression of tyrosine kinase 
receptors and their ligands, c-kit or mutation of the PTEN tumour suppressor gene. 
Molecular cloning identified an additional family, whose catalytic domains bear 
resemblance to PI3K. Based on their sequence homology, the kinases were named PI3K-
related kinases (PIKKs). They include several subfamilies such as the TOR family, ataxia 
telangiectasia gene product and the DNA-dependent protein kinase (Kirkwood et al., 2006). 
In melanoma therapy, the TOR subfamily is targeted by rapamycin and its analogues 
RAD001, AP23573m and CCI-779, from which especially the last molecule seems to have 
a promising therapeutic effect. Toxicity is mild, predominantly comprised of stomatitis, 
diarrhoea, a skin rash and hyperlipidemia. 
R115777 (tipifarnib) 
Farnesyl transferase inhibitors (FTIs) inhibit the farnesylation of proteins, which are 
involved in RAS downstream signalling pathway including the RAF-MEK-ERK (MAPK) 
and PI3K-AKT-mTOR (AKT). They have a major role in melanoma progression. Current 
findings suggest that R115777 inhibits mTOR signalling and may therefore represent an 
effective alternative for melanoma treatment. In particular, the combination of the FTI with 
the RAS inhibitor sorafenib synergistically inhibited melanoma cell growth, significantly 
enhanced sorafenib-induced apoptosis and completely suppressed invasive tumour growth. 
Imatinib 
The presence of c-kit and PDGF on the surface of at least some melanomas encouraged the 
exploration of these agents in melanoma patients. Imatinib is known as a c-kit and PDGF 
inhibitor.  But an imatinib phase II study showed no objective clinical responses and no 
patient was progression-free at 6 months. Moreover, significant grade 3 and 4 toxicity was 
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observed (Sosman & Puzanov, 2011). Based on the results, it was concluded that imatinib is 
inactive as single-agent therapy for metastatic melanoma. 
Erlotinib 
Erlotinib is a small-molecule inhibitor specific for the EGFR kinase, based on competing 
with ATP for binding to the intracellular catalytic domain of the receptor kinase, thereby 
inhibiting autophosphorylation of the receptor critical for binding to downstream signalling 
proteins. Whereas no influence on tumour cell proliferation was seen with erlotinib 
monotherapy, preclinical studies demonstrated decreased invasive potential of its 
combination with bevacizumab (anti-VEGF therapy), providing promising rationale for 
clinical studies. 
2.4.3 Reversing resistance to apoptosis 
One of the major consequences of the constitutive activation of the MAPK and PI3K/AKT 
pathways is the induction of tumour cell resistance to apoptosis. This resistance is believed 
to be an element of the resistance of melanoma to the classical therapy. Members of the anti-
apoptotic Bcl-2 family have been successfully targeted to render tumour cells more 
susceptible to apoptosis. 
Oblimersen sodium is an anti-Bcl-2 oligonucleotide that selectively targets Bcl-2 RNA for 
degradation by RNase H, thereby decreasing Bcl-2 protein production. Although the drug 
did not increase overall survival, the application was associated with a significant increase 
of durable response (exceeding 6 months). The use of oblimersen can improve multiple 
outcomes in patients with advanced melanoma in combination with dacarbazine. The 
adverse effects of the therapy include fever, neutropenia and thrombocytopenia (Tawbi & 
Nimmagadda, 2009). 
Another targeted molecule of this class is survivin, which has been found to be highly 
expressed in most cancers. YM155 is a small molecule that has been demonstrated in 
preclinical models to suppress the function of survivin. 
2.4.4 Inhibitors of the proteasome 
The proteasome is a multienzyme complex that serves as a major protein in degradation 
pathway. The proteasome controls the levels of proteins that are important for cell cycle 
progression and apoptosis including cyclins, caspases, Bcl-2, and NF-kappaB. In cancers, 
deregulation of the ubiquitin-proteasome pathway may contribute to tumour progression, 
drug resistance and altered immune surveillance. Bortezomib was identified as a leading 
candidate of proteasome inhibitors correlated with growth-inhibitory effect. But a phase II 
study of bortezomib was terminated due to a lack of responses, and it was concluded that 
single-agent bortezomib administration was not efficacious in metastatic melanoma. 
Patients demonstrated grade 3 toxicity including sensory neuropathy, thrombocytopenia, 
constipation, fatigue, ileus and infections without neutropenia. 
2.4.5 Anti-angiogenic therapy 
Targeting tumour angiogenesis has several advantages over standard chemotherapy 
including independence on tumour cell resistance, broad applicability to tumour of different 
histogenesis and the potential to develop very specific therapies with minimal toxicities, 
because neoangiogenesis is not required for normal adult tissues. Because VEGF has a key 
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role in tumour angiogenesis, numerous compounds have been developed to counteract its 
angiogenic effect. 
Bevacizumab 
Bevacizumab is an anti-VEGF monoclonal antibody, received FDA approval for colorectal 
cancer therapy in US in 2005 (Kirkwood et al., 2006).  Bevacizumab is currently being tested 
in metastatic melanoma. The effect of bevacizumab on tumour cells is indirect and not 
necessarily lethal with no direct anti-proliferative effect. This is probably why as a single 
agent it is not very active, but bevacizumab therapy seems to be promising when combined 
with anti-proliferative agents. It is combined with low- and high-dose IFN-alpha. This  
chemotherapy is comprised of  carboplatin and paclitaxel, imatinib mesylate, and lastly with 
erlotinib. The addition of bevacizumab to conventional chemotherapy has been shown to 
control tumour growth and progression more effectively than chemotherapy alone. This is 
probably explained by bevacizumab´s ability to dampen the effect of VEGF up-regulation 
induced by chemotherapy. Adverse response include infrequently increased risk of grade 
3/4 hypertension, but also bleeding relating death was documented (Yang et al., 2010). 
Anti-angiogenic  isoforms of VEGF 
These isoforms are generated by differential splicing of exon 8 being widely expressed in 
normal human tissue but down-regulated in cancer. Endogenous anti-angiogenic VEGF 
isoforms are cytoprotective for endothelial, epithelial and neuronal cells suggesting both an 
improved safety profile and an explanation for unpredictable anti-VEGF side effects. It has 
been demonstrated that administration of recombinant VEGF(165)b inhibits angiogenesis in 
colorectal carcinoma and malignant melanoma. Splicing factors and their regulatory 
molecules alter splice site selection and cells can switch from the anti-angiogenic VEGF 
isoforms to the pro-angiogenic ones. Splice site selection in cancer opens up the possibility 
of using splicing factor inhibitors as novel anti-angiogenic therapeutics. 
Thalidomide  
The precise mechanism of thalidomide anti-angiogenic activity remains unknown, however 
some of its effect may result from blocking angiogenic factors such as VEGF. Thalidomide 
has also been suggested to have immunomodulating effect by decreasing cyclooxygenase-2 
activity. Thalidomide is a potent inhibitor TNF-alpha and decreases the density of 
TNF-alpha induced adhesion molecules such as ICAM-1 and VCAM. Thalidomide also 
causes induction of NK (natural killer) cells and increases the levels of IL-1, IL-2 receptors 
and INF-gamma leading to tumour cell lysis and modulates immune system to induce 
anticancer activity. Thalidomide has also antiproliferative and proapototic properties 
through induction of cell growth arrest at the G1 phase, downregulation of NF-kappaB and 
activation of caspase 8 (Tawbi & Nimmagada, 2009). Because thalidomide alone showed 
poor activity, various combination have been used in metastatic melanoma. 
The combinations, however, failed to demonstrate clinical efficacy. 
The main toxicities are dose-dependent neuropathy, constipation, anorexia, skin rash, 
fatigue, but to the most serious belong deep venous thrombosis and pulmonary embolism. 
Vitaxin (MEDI-552) 
Vitaxin is a monoclonal antibody targeted against the ǂvǃ3 integrin expressed by 
endothelial and melanoma cells but not by normal melanocytes. Tumours from patients 
with stage IV melanoma seem to express  the integrin more intensely. MEDI-552 potentially 
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blocks tumour growth causing cell apoptosis and impairment of angiogenesis. The drug 
alone showed no objective response, whereas the combination with chemotherapy 
demonstated mild response rate. Grade 3  and 4 adverse events were chiefly neutropenia 
and thrombocytopenia (Sosman & Puzanov, 2011). 
2.4.6 Immunotherapy   
IL-2 is a potent immune modulator that stimulates activation and proliferation of 
T lymphocytes. Treatment with high-dose IL-2 leads to objective tumour responses. 
Treatment is typically reserved for younger, fitter patients and requires intensive 
monitoring. The therapy is associated with substantial toxicity including oliguria, renal 
failure, hepatotoxicity, edema, sepsis, and death  (Algazi et al., 2010). 
IL-2 with peptide vaccination 
Recent data suggest that vaccination against the melanoma peptide antigen gp-100 may 
improve the efficacy of high-dose IL-2 (Algazi et al., 2010). 
Anti-CTLA4 antibodies 
The T cell surface protein, CTLA4, competes with CD28 for B7. It is a second surface protein of 
antigen presenting cells that acts as a costimulatory molecule for T lymphocytes. Binding of 
CTLA4 to B7 inhibits T-cell proliferation, thus anti-CTLA4 antibodies have been developed to 
abrogate these inhibitory interactions and break immune tolerance to melanoma. Ipilimumab 
is an anti-CTLA4 antibody that have led to modest rates of objective tumour response. 
Common observed toxicities included grade 3 and 4 immune-related events such as colitis, 
dermatitis, hepatitis, acute pancreatitis and hypophysitis (Di Giacomo et al., 2011). 
Combined approaches are already being tested. Some of the most promising combination 
development are listed in Table 2. All trials are planned with an emphasis on tumour 
biology. Molecular characterization of the tumour before the therapy followed by treatment 
examining inhibitory effects on the targets will be critical to understand the clinical results. 
 
Sorafenib + bevacizumab 
Sorafenib + CCI-779 
Sorafenib + R115777 
Bevacizumab + CCI-779 
Bevacizumab + R115777  
Table 2. The most promising combinations  for melanoma therapy 
3. Conclusions 
Stroma alterations in malignant melanoma are observed already in early stage tumours and 
are further cumulated as tumours progress. A deeper understanding the factors modulating 
melanoma microenvironment is necessary and would potentially lead to a new therapeutic 
approach. 
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